INCYTE’S FIRST-IN-CLASS MUTCALR-TARGETED MONOCLONAL ANTIBODY, INCA033989, GRANTED BREAKTHROUGH THERAPY DESIGNATION BY U.S. FDA

Reuters · 1d ago

Please log in to view news